215 related articles for article (PubMed ID: 31783044)
1. MSH6 immunohistochemical heterogeneity in colorectal cancer: comparative sequencing from different tumor areas.
Chen W; Pearlman R; Hampel H; Pritchard CC; Markow M; Arnold C; Knight D; Frankel WL
Hum Pathol; 2020 Feb; 96():104-111. PubMed ID: 31783044
[TBL] [Abstract][Full Text] [Related]
2. Universal screening for Lynch syndrome in endometrial cancers: frequency of germline mutations and identification of patients with Lynch-like syndrome.
Dillon JL; Gonzalez JL; DeMars L; Bloch KJ; Tafe LJ
Hum Pathol; 2017 Dec; 70():121-128. PubMed ID: 29107668
[TBL] [Abstract][Full Text] [Related]
3. Immunohistochemical staining for DNA mismatch repair proteins in intestinal tract carcinoma: how reliable are biopsy samples?
Shia J; Stadler Z; Weiser MR; Rentz M; Gonen M; Tang LH; Vakiani E; Katabi N; Xiong X; Markowitz AJ; Shike M; Guillem J; Klimstra DS
Am J Surg Pathol; 2011 Mar; 35(3):447-54. PubMed ID: 21297438
[TBL] [Abstract][Full Text] [Related]
4. Lynch Syndrome in Thai Endometrial Cancer Patients.
Manchana T; Ariyasriwatana C; Triratanachat S; Phowthongkum P
Asian Pac J Cancer Prev; 2021 May; 22(5):1477-1483. PubMed ID: 34048176
[TBL] [Abstract][Full Text] [Related]
5. A Comprehensive Study of Heterogeneous Mismatch Repair Expression in Solid Tumors Reveals Different Immunohistochemical Patterns and Distinct Genetic Mechanisms.
Wang J; Zhang Z; Cai Y; Lu J; Zhang H; Pang J; Wu H; Liang Z
Am J Surg Pathol; 2024 Apr; 48(4):417-425. PubMed ID: 37997470
[TBL] [Abstract][Full Text] [Related]
6. Lessons learnt from implementation of a Lynch syndrome screening program for patients with gynaecological malignancy.
Najdawi F; Crook A; Maidens J; McEvoy C; Fellowes A; Pickett J; Ho M; Nevell D; McIlroy K; Sheen A; Sioson L; Ahadi M; Turchini J; Clarkson A; Hogg R; Valmadre S; Gard G; Dooley SJ; Scott RJ; Fox SB; Field M; Gill AJ
Pathology; 2017 Aug; 49(5):457-464. PubMed ID: 28669579
[TBL] [Abstract][Full Text] [Related]
7. Heterogenous loss of mismatch repair (MMR) protein expression: a challenge for immunohistochemical interpretation and microsatellite instability (MSI) evaluation.
McCarthy AJ; Capo-Chichi JM; Spence T; Grenier S; Stockley T; Kamel-Reid S; Serra S; Sabatini P; Chetty R
J Pathol Clin Res; 2019 Apr; 5(2):115-129. PubMed ID: 30387329
[TBL] [Abstract][Full Text] [Related]
8. Immunohistochemical null-phenotype for mismatch repair proteins in colonic carcinoma associated with concurrent MLH1 hypermethylation and MSH2 somatic mutations.
Wang T; Stadler ZK; Zhang L; Weiser MR; Basturk O; Hechtman JF; Vakiani E; Saltz LB; Klimstra DS; Shia J
Fam Cancer; 2018 Apr; 17(2):225-228. PubMed ID: 28819720
[TBL] [Abstract][Full Text] [Related]
9. Value of immunohistochemical detection of DNA mismatch repair proteins in predicting germline mutation in hereditary colorectal neoplasms.
Shia J; Klimstra DS; Nafa K; Offit K; Guillem JG; Markowitz AJ; Gerald WL; Ellis NA
Am J Surg Pathol; 2005 Jan; 29(1):96-104. PubMed ID: 15613860
[TBL] [Abstract][Full Text] [Related]
10. Germline MLH1 Mutations Are Frequently Identified in Lynch Syndrome Patients With Colorectal and Endometrial Carcinoma Demonstrating Isolated Loss of PMS2 Immunohistochemical Expression.
Dudley B; Brand RE; Thull D; Bahary N; Nikiforova MN; Pai RK
Am J Surg Pathol; 2015 Aug; 39(8):1114-20. PubMed ID: 25871621
[TBL] [Abstract][Full Text] [Related]
11. Association of tumor morphology with mismatch-repair protein status in older endometrial cancer patients: implications for universal versus selective screening strategies for Lynch syndrome.
Rabban JT; Calkins SM; Karnezis AN; Grenert JP; Blanco A; Crawford B; Chen LM
Am J Surg Pathol; 2014 Jun; 38(6):793-800. PubMed ID: 24503759
[TBL] [Abstract][Full Text] [Related]
12. MLH1/PMS2-deficient Endometrial Carcinomas in a Universally Screened Population: MLH1 Hypermethylation and Germline Mutation Status.
Kurpiel B; Thomas MS; Mubeen M; Ring KL; Modesitt SC; Moskaluk CA; Mills AM
Int J Gynecol Pathol; 2022 Jan; 41(1):1-11. PubMed ID: 33577226
[TBL] [Abstract][Full Text] [Related]
13. Immunohistochemistry for PMS2 and MSH6 alone can replace a four antibody panel for mismatch repair deficiency screening in colorectal adenocarcinoma.
Hall G; Clarkson A; Shi A; Langford E; Leung H; Eckstein RP; Gill AJ
Pathology; 2010; 42(5):409-13. PubMed ID: 20632815
[TBL] [Abstract][Full Text] [Related]
14. Isolated Loss of PMS2 Immunohistochemical Expression is Frequently Caused by Heterogenous MLH1 Promoter Hypermethylation in Lynch Syndrome Screening for Endometrial Cancer Patients.
Kato A; Sato N; Sugawara T; Takahashi K; Kito M; Makino K; Sato T; Shimizu D; Shirasawa H; Miura H; Sato W; Kumazawa Y; Sato A; Kumagai J; Terada Y
Am J Surg Pathol; 2016 Jun; 40(6):770-6. PubMed ID: 26848797
[TBL] [Abstract][Full Text] [Related]
15. Secondary mutation in a coding mononucleotide tract in MSH6 causes loss of immunoexpression of MSH6 in colorectal carcinomas with MLH1/PMS2 deficiency.
Shia J; Zhang L; Shike M; Guo M; Stadler Z; Xiong X; Tang LH; Vakiani E; Katabi N; Wang H; Bacares R; Ruggeri J; Boland CR; Ladanyi M; Klimstra DS
Mod Pathol; 2013 Jan; 26(1):131-8. PubMed ID: 22918162
[TBL] [Abstract][Full Text] [Related]
16. Universal Lynch Syndrome Screening Should be Performed in All Upper Tract Urothelial Carcinomas.
Ju JY; Mills AM; Mahadevan MS; Fan J; Culp SH; Thomas MH; Cathro HP
Am J Surg Pathol; 2018 Nov; 42(11):1549-1555. PubMed ID: 30148743
[TBL] [Abstract][Full Text] [Related]
17. Germline mismatch repair gene variants analyzed by universal sequencing in Japanese cancer patients.
Kiyozumi Y; Matsubayashi H; Horiuchi Y; Higashigawa S; Oishi T; Abe M; Ohnami S; Urakami K; Nagashima T; Kusuhara M; Miyake H; Yamaguchi K
Cancer Med; 2019 Sep; 8(12):5534-5543. PubMed ID: 31386297
[TBL] [Abstract][Full Text] [Related]
18. Isolated loss of PMS2 expression in colorectal cancers: frequency, patient age, and familial aggregation.
Gill S; Lindor NM; Burgart LJ; Smalley R; Leontovich O; French AJ; Goldberg RM; Sargent DJ; Jass JR; Hopper JL; Jenkins MA; Young J; Barker MA; Walsh MD; Ruszkiewicz AR; Thibodeau SN
Clin Cancer Res; 2005 Sep; 11(18):6466-71. PubMed ID: 16166421
[TBL] [Abstract][Full Text] [Related]
19. [Correlation between mismatch-repair protein expression and clinicopathologic features in 658 colorectal cancers].
Hu XR; Xu C; Kang Y; Wang T; Zhang Y; Yang XH
Zhonghua Bing Li Xue Za Zhi; 2018 Nov; 47(11):827-833. PubMed ID: 30423605
[No Abstract] [Full Text] [Related]
20. Heterogenous mismatch-repair status in colorectal cancer.
Joost P; Veurink N; Holck S; Klarskov L; Bojesen A; Harbo M; Baldetorp B; Rambech E; Nilbert M
Diagn Pathol; 2014 Jun; 9():126. PubMed ID: 24968821
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
